Relmada (RLMD) Q3 2026 Earnings Call Transcript
Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.
How this was made

The 30-second read
Why it matters
The disclosed Phase 2 durability data and IND filing timeline provide fresh, material information that could move the stock, especially given the company's cash position to fund upcoming trials.
Market read
First‑time disclosure of robust Phase 2 outcomes and IND plans makes this a high‑novelty biotech news item with potential short‑term price impact.
What to watch
Cash runway is sufficient, but the company remains loss‑making; dilution risk if additional capital is needed.
Background
Relmada (RLMD) held its Q3 2026 earnings call, presenting updated financials and detailed clinical progress on its lead candidates NDV‑01 (bladder cancer) and sepranolone (Prader‑Willi syndrome).
Ticker impact
Relmada reported Phase 2 18‑month data for NDV‑01 showing 86% CR durability and announced IND filing plans for year‑end 2026, plus cash runway to 2029.
likely upward pressure as investors price in successful trial data and upcoming IND filing.
Data are first‑time disclosed, clinically material, and indicate a clear path to Phase 3, which typically lifts biotech stocks.
Market effects
Strengthens the oncology‑focused biotech sector with a new intravesical therapy candidate.
U.S. biotech market may see modest gains as investors reassess early‑stage oncology pipelines.
Limited to biotech investors; no broad macro impact.
Counterpoint
If Phase 3 enrollment delays occur, the stock could face disappointment despite strong Phase 2 data.
Key entities
- companyRelmada Therapeutics
Biopharma developing NDV‑01 and sepranolone.
- productNDV‑01
Sustained‑release intravesical formulation for NMIBC.



